Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 2, 2011, Pages 126-132

  Qian, Xueya ^a   Xi, Xiaowei ^a   Li, Linxia ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

epithelial ovarian carcinoma; prognosis; Survivin

Indexed keywords

CARBOPLATIN; CELL NUCLEUS ANTIGEN; FORMALDEHYDE; PACLITAXEL; PARAFFIN; POLYCLONAL ANTIBODY; SURVIVIN; TUMOR MARKER;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CELL NUCLEUS; CYSTADENOMA; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; SCORING SYSTEM; STAINING; TISSUE SECTION;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL NUCLEUS; CYSTADENOMA; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79951948383     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181e30dcd     Document Type: Article

References (39)

1. FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2003;83(suppl 1):ix-xxii, 1-229.
2. Borst P, Borst J, Smets LA. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resist Updat. 2001;4: 129-131. (Pubitemid 32619570)
3. Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist Updat. 2001;4:132-134. (Pubitemid 32619571)
4. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999;13:239-252.
5. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584. (Pubitemid 28563719)
6. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000-5005.
7. Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx3 and survivin-2B, in bladder cancer. Cancer Detect Prev. 2009;32:308-313.
8. Ponnelle T, Chapusot C, Martin L, et al. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol. 2005;131:504-510. (Pubitemid 41215305)
9. Saito T, Arifin MT, Hama S, et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol. 2007;82:193-198. (Pubitemid 46431865)
10. Bria E, Visca P, Novelli F, et al. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-smallcell lung cancer. Eur J Surg Oncol. 2008;34:593-598. (Pubitemid 351514886)
11. Span PN, Sweep FC, Wiegerinck ET, et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem. 2004;50:1986-1993. (Pubitemid 39425834)
12. Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology. 2000; 31:1080-1085. (Pubitemid 30233232)
13. Piras F, Murtas D, Minerba L, et al. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology. 2007;50:835-842. (Pubitemid 46850069)
14. Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002;184:105-116. (Pubitemid 34718112)
15. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol. 2006;208:476-486. (Pubitemid 44141872)
16. Fortugno P, Wall NR, Giodini A, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci. 2002;115(Pt 3):575-585. (Pubitemid 34182984)
17. Tavassoli FA, Devilee P. Tumours of the ovary and peritoneum. In: Tavassoli FA, Devilee P, eds. World Health Organization: Tumours of the Breast and Female Genital Organs (WHo/IARC Classification of Tumours). 1st ed. IARCPress: WHO; 2003:138-139.
18. Takai N, Miyazaki T, Nishida M, et al. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int J Mol Med. 2002;10:211-216.
19. Cohen C, Lohmann CM, Cotsonis G, et al. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol. 2003;16:574-583. (Pubitemid 36718439)
20. Connell CM, Wheatley SP, McNeish IA. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res. 2008;68:7923-7931.
21. Calder KB, Khalil FK, Schlauder S, et al. Immunohistochemical expression of survivin in cutaneous sebaceous lesions. Am J Dermatopathol. 2008;30:545-548.
22. Adamkov M, Lauko L, Balentova S, et al. Expression pattern of anti-apoptotic protein survivin in dysplastic nevi. Neoplasma. 2009; 56:130-135.
23. Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep. 2009; s22:557-562.
24. Younis T, Haché KD, Rayson D, et al. Survivin and COX-2 expression in male breast carcinoma. Breast. 2009;18:228-232.
25. Li F, Yang J, Ramnath N, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 2005;114:509-512. (Pubitemid 40349608)
26. Yoshida H, Ishiko O, Sumi T, et al. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and seroustype ovarian carcinomas. Int J Oncol. 2001;19:537-542.
27. Lin CK, Chao TK, Yu CP, et al. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 2009;117:162-175.
28. Tringler B, Lehner R, Shroyer AL, et al. Immunohistochemical localization of survivin in serous tumors of the ovary. Appl Immunohistochem Mol Morphol. 2004;12:40-43. (Pubitemid 38332318)
29. Kleinberg L, Flørenes VA, Silins I, et al. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109:228-238. (Pubitemid 46106237)
30. Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204:241-249. (Pubitemid 351377530)
31. Ferrandina G, Legge F, Martinelli E, et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer. 2005;92:271-277. (Pubitemid 40343140)
32. Mahotka C, Liebmann J, Wenzel M, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002;9:1334-1342. (Pubitemid 36097703)
33. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4: 174-191. (Pubitemid 350171819)
34. Ling X, Yang J, Tan D, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer. 2005;49:353-361. (Pubitemid 41139148)
35. Végran F, Boidot R, Oudin C, et al. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene. 2007;26:290-297. (Pubitemid 46095740)
36. Caldas H, Jiang Y, Holloway MP, et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene. 2005;24:1994-2007. (Pubitemid 40520508)
37. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005; 4:11.
38. Pisarev V, Yu B, Salup R, et al. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res. 2003;9:6523-6533. (Pubitemid 38031841)
39. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133-1139. (Pubitemid 47062670)